Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences.

Jacqueline C Barrientos,Ayed O Ayed,Agnes Cha,Senxi Du,Bruno Fang,Ryan Hall,Stanley M Marks,Eileen Peng,Joanna M Rhodes,Kellie Ryan,Sharon B Winters,Percy L Yeung,Jing-Zhou Hou

Targeted oncology（2023）

引用 0|浏览5

暂无评分

摘要

Toxicity and disease progression were the most common reasons for ibrutinib discontinuations in the overall population and among Black patients, respectively. Encouraging research participation of underrepresented patient groups will help clinicians better understand treatment outcomes.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要